Table 2 Comparison of ALT, HBV DNA, HBeAg seroconversion and HBsAg during treatment and follow-up between the responders and nonresponders
Variables | Rs | NRs | P-value |
|---|---|---|---|
The number of patients | 12 | 34 | |
ALT normalization (n,%) | |||
Months 3 | 5(41.7%) | 15(44.1%) | 1.0000 |
Months 6 | 8(66.7%) | 21(61.7%) | 1.0000 |
Months 12 | 10(83.3%) | 26(76.5%) | 1.0000 |
Six-month follow-up | 12(100%) | 24(70.6%) | 0.0439 |
HBV DNA undetectability (n,%) | |||
Months 3 | 6(50.0%) | 12(35.3%) | 0.4949 |
Months 6 | 10(83.3%) | 16(47.1%) | 0.0430 |
Months 12 | 12(100%) | 20(58.8%) | 0.0088 |
Six-month follow-up | 12(100%) | 19(55.9%) | 0.0042 |
HBeAg seroconversion | |||
Months 12 | 10(83.3%) | 11(32.4%) | 0.0055 |
Six-month follow-up | 12(100%) | 11(32.4%) | <0.0001 |
HBsAg (log IU/mL) | |||
Months 3 | 3.5±0.5 | 4.1±0.4 | 0.0001 |
Months 6 | 3.1±0.7 | 3.9±1.1 | 0.0235 |
Months 12 | 2.9±0.4 | 3.7±0.9 | 0.0049 |
Six-month follow-up | 2.5±0.6 | 3.8±0.7 | <0.0001 |